Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis and applications of respiratory surface EMG: report of a round table meeting.

Critical care (London, England)·2024
Same author

Absence of COVID-19 associated mucormycosis in a tertiary intensive care unit in the Netherlands.

Scientific reports·2023
Same author

A luminous fast radio burst that probes the Universe at redshift 1.

Science (New York, N.Y.)·2023
Same author

Computational physiological models for individualised mechanical ventilation: a systematic literature review focussing on quality, availability, and clinical readiness.

Critical care (London, England)·2023
Same author

Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety.

Journal of anesthesia, analgesia and critical care·2023
Same author

Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005.

Journal of the American Society of Nephrology : JASN·2023
Same journal

List of guest reviewers.

Heart, lung and vessels·2018
Same journal

Resting energy expenditures in haemodynamically compromised cardiac patients.

Heart, lung and vessels·2016
Same journal

Surgical therapy for complications of pneumonia on extracorporeal membrane oxygenation can improve the ability to wean patients from support.

Heart, lung and vessels·2016
Same journal

Hypothermic lung edema after accidental hypothermia with out of hospital cardiac arrest.

Heart, lung and vessels·2016
Same journal

Improved detection of an intravascular catheter using dual energy subtraction radiography.

Heart, lung and vessels·2016
Same journal

Pitfalls in percutaneous ECMO cannulation.

Heart, lung and vessels·2016
See all related articles

Related Experiment Video

Updated: May 4, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K

Levosimendan: current data, clinical use and future development.

M S Nieminen1, S Fruhwald2, L M A Heunks3

  • 1Heart and Lung Center, University of Helsinki Central Hospital, Helsinki, Finland.

Heart, Lung and Vessels
|December 24, 2013
PubMed
Summary
This summary is machine-generated.

Levosimendan enhances heart function by increasing contractility and vasodilation without raising oxygen demand. This inodilator offers benefits in acute heart failure and other critical conditions.

Keywords:
acute heart failurecardiac surgerycardioprotective inodilatorlevosimendanreviewshock

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

10.8K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K

Related Experiment Videos

Last Updated: May 4, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

10.8K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Levosimendan is an inodilator used for acutely decompensated severe chronic heart failure.
  • Its mechanism involves calcium sensitization of troponin C, vasodilation, and cardioprotection via potassium-ATP channel opening.

Purpose of the Study:

  • To summarize the pharmacological effects and clinical applications of levosimendan.
  • To evaluate its efficacy and safety in various cardiovascular conditions.

Main Methods:

  • Clinical trial data analysis.
  • Review of pharmacological properties and therapeutic outcomes.

Main Results:

  • Levosimendan improves hemodynamics and heart failure symptoms without increasing cardiac oxygen consumption.
  • It shows favorable effects on neurohormone levels and is well-tolerated, with common side effects including hypotension and headache.
  • Positive effects observed in cardiac surgery, advanced chronic heart failure, and conditions like cardiogenic shock.

Conclusions:

  • Levosimendan is an effective inodilator for acute heart failure and other critical cardiovascular conditions.
  • It offers hemodynamic and cardioprotective benefits with a generally favorable safety profile.